← Open Payments lookup

NPI 1285611871: Open Payments

NPI 1285611871. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,632 in 66 payments from 16 companies in 2025. Trend: 2023 $1,300 · 2024 $1,831 · 2025 $1,632

Food & beverage: $1,632
CompanyPaymentsAmount
Novo Nordisk Inc7$311
ABBVIE INC.13$285
PFIZER INC.14$199
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)8$193
Axsome Therapeutics, Inc.3$137
GlaxoSmithKline, LLC.5$89
Bayer Healthcare Pharmaceuticals Inc.3$83
Abbott Laboratories1$80
Otsuka America Pharmaceutical, Inc.3$56
Lilly USA, LLC2$48

Products named: CAPLYTA, UBRELVY, Ozempic, Auvelity, Wegovy, ELIQUIS, QULIPTA, Kerendia.